OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 149.2 Million CAD | 2.33% |
| 2022 | 145.8 Million CAD | 84.19% |
| 2021 | 79.16 Million CAD | -8.79% |
| 2020 | 86.79 Million CAD | 7.94% |
| 2019 | 80.41 Million CAD | 546.98% |
| 2018 | 12.42 Million CAD | 117.53% |
| 2017 | 5.71 Million CAD | -6.76% |
| 2016 | 6.12 Million CAD | 521.04% |
| 2015 | 986.67 Thousand CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 36.45 Million CAD | -20.82% |
| 2024 Q2 | 37.62 Million CAD | 3.22% |
| 2024 Q3 | 41.06 Million CAD | 9.12% |
| 2023 Q3 | 32.78 Million CAD | -16.99% |
| 2023 FY | 149.2 Million CAD | 2.33% |
| 2023 Q1 | 43.32 Million CAD | -4.75% |
| 2023 Q2 | 39.49 Million CAD | -8.84% |
| 2023 Q4 | 46.04 Million CAD | 40.43% |
| 2022 Q2 | 31.83 Million CAD | 4.8% |
| 2022 Q3 | 38.11 Million CAD | 19.72% |
| 2022 Q4 | 45.48 Million CAD | 19.32% |
| 2022 FY | 145.8 Million CAD | 84.19% |
| 2022 Q1 | 30.37 Million CAD | 22.17% |
| 2021 Q4 | 24.86 Million CAD | 22.34% |
| 2021 Q1 | 19.33 Million CAD | -5.24% |
| 2021 Q2 | 14.64 Million CAD | -24.25% |
| 2021 FY | 79.16 Million CAD | -8.79% |
| 2021 Q3 | 20.32 Million CAD | 38.8% |
| 2020 FY | 86.79 Million CAD | 7.94% |
| 2020 Q1 | 25.15 Million CAD | 54.41% |
| 2020 Q2 | 23.22 Million CAD | -7.68% |
| 2020 Q3 | 18.02 Million CAD | -22.39% |
| 2020 Q4 | 20.4 Million CAD | 13.2% |
| 2019 FY | 80.41 Million CAD | 546.98% |
| 2019 Q2 | 26.93 Million CAD | 116.53% |
| 2019 Q4 | 16.29 Million CAD | -34.18% |
| 2019 Q3 | 24.75 Million CAD | -8.11% |
| 2019 Q1 | 12.43 Million CAD | 434.55% |
| 2018 Q3 | 3.72 Million CAD | 1.01% |
| 2018 Q4 | 2.32 Million CAD | -37.55% |
| 2018 FY | 12.42 Million CAD | 117.53% |
| 2018 Q2 | 3.68 Million CAD | 37.32% |
| 2018 Q1 | 2.68 Million CAD | 25.14% |
| 2017 FY | 5.71 Million CAD | -6.76% |
| 2017 Q4 | 2.14 Million CAD | 11.95% |
| 2017 Q1 | 2.23 Million CAD | 19.55% |
| 2017 Q2 | -581.16 Thousand CAD | -126.05% |
| 2017 Q3 | 1.91 Million CAD | 429.94% |
| 2016 Q4 | 1.86 Million CAD | 3.27% |
| 2016 FY | 6.12 Million CAD | 521.04% |
| 2016 Q3 | 1.8 Million CAD | 26.75% |
| 2016 Q2 | 1.42 Million CAD | 38.48% |
| 2016 Q1 | 1.02 Million CAD | 52.38% |
| 2015 Q2 | 67.97 Thousand CAD | 417.99% |
| 2015 Q1 | 13.12 Thousand CAD | 0.0% |
| 2015 FY | 986.67 Thousand CAD | 0.0% |
| 2015 Q4 | 675.53 Thousand CAD | 193.64% |
| 2015 Q3 | 230.05 Thousand CAD | 238.46% |
| 2014 Q3 | - CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Theratechnologies Inc. | 81.76 Million USD | -82.483% |
| Harrow Health, Inc. | 130.19 Million USD | -14.603% |
| Dynavax Technologies Corporation | 232.28 Million USD | 35.766% |
| Biofrontera Inc. | 34.07 Million USD | -337.924% |
| Cronos Group Inc. | 88.84 Million USD | -67.947% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -1071.616% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 66.299% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -2190.823% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -277.233% |
| Radius Health, Inc. | 2.88 Billion USD | 94.823% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -361.811% |
| DURECT Corporation | 8.54 Million USD | -1645.499% |
| ProPhase Labs, Inc. | 44.38 Million USD | -236.169% |
| Safety Shot Inc | 202.67 Thousand USD | -73519.797% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 85.339% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -7636.867% |
| Alvotech | 91.43 Million USD | -63.184% |
| Assertio Holdings, Inc. | 152.06 Million USD | 1.883% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 75.44% |
| Rockwell Medical, Inc. | 83.61 Million USD | -78.45% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -519.294% |
| Procaps Group S.A. | 409.92 Million USD | 63.601% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 67.869% |
| SCYNEXIS, Inc. | 140.14 Million USD | -6.468% |
| Aytu BioPharma, Inc. | 81 Million USD | -84.199% |
| Viatris Inc. | 15.42 Billion USD | 99.033% |
| OptiNose, Inc. | 70.98 Million USD | -110.187% |
| SIGA Technologies, Inc. | 139.91 Million USD | -6.638% |
| Tilray Brands, Inc. | 788.94 Million USD | 81.088% |
| PetIQ, Inc. | 1.1 Billion USD | 86.46% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -519.294% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 92.093% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -1118.146% |
| Alimera Sciences, Inc. | 80.75 Million USD | -84.765% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 73.674% |
| Silver Spike Investment Corp. | 11.72 Million USD | -1172.851% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 65.553% |
| Journey Medical Corporation | 79.18 Million USD | -88.436% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -2462.613% |
| Alpha Teknova, Inc. | 36.68 Million USD | -306.731% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -756.664% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -16.329% |
| PainReform Ltd. | - USD | -Infinity% |
| Cosmos Health Inc. | 53.37 Million USD | -179.532% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -433.581% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -11359.696% |
| Embecta Corp. | 1.12 Billion USD | 86.688% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | 651 Thousand USD | -22819.392% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 77.895% |
| Incannex Healthcare Limited | 12 Thousand USD | -1243277.025% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -13761.441% |
| Shineco, Inc. | 9.8 Million USD | -1422.214% |
| Procaps Group, S.A. | 409.92 Million USD | 63.601% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 69.351% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -194.971% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 88.491% |
| Alvotech | 91.43 Million USD | -63.184% |
| Hempacco Co., Inc. | 4.04 Million USD | -3588.053% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | 52.874% |
| Bright Green Corporation | 401.49 Thousand USD | -37062.786% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -28.256% |
| Kamada Ltd. | 144.75 Million USD | -3.072% |
| Indivior PLC | 1.09 Billion USD | 86.349% |
| Evoke Pharma, Inc. | 5.18 Million USD | -2780.06% |
| Flora Growth Corp. | 76.07 Million USD | -96.139% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -13761.441% |
| Evolus, Inc. | 202.08 Million USD | 26.167% |
| HUTCHMED (China) Limited | 837.99 Million USD | 82.195% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 76.846% |
| Akanda Corp. | 2.16 Million USD | -6807.484% |